1. Phylogeny  
TNNI3K is a cardiac‐restricted serine/threonine kinase that is evolutionarily conserved across mammals and exhibits a high degree of tissue specificity, being expressed predominantly in cardiomyocytes (milano2015tnni3kincardiovascular pages 1-2). TNNI3K belongs to the mixed-lineage kinase family and is frequently discussed in proximity to integrin‐linked kinase (ILK) due to its similar domain organization and shared evolutionary origins with other MAP kinase kinase kinase (MAPKKK) subfamily members (lal2014troponiniinteractingprotein pages 2-3). Phylogenetic analyses using conserved kinase domains have consistently placed TNNI3K in close relationship with other MAPKKKs such as TAK1, Raf-1, and MLK2, which are instrumental in diverse signaling cascades throughout eukaryotes (zhao2003cloningandcharacterization pages 2-3). Furthermore, the presence of conserved N-terminal ankyrin repeats alongside a central catalytic domain indicates that TNNI3K shares a common ancestor with kinases that evolved to mediate specialized functions in muscle contractility, an adaptation that is apparent in its retention exclusively in the cardiac lineage (milano2015tnni3kincardiovascular pages 2-3, pham2021thediverseroles pages 1-3). Its genetic conservation and restricted expression pattern have been demonstrated in multiple murine strains as well as in human cardiac tissue, underscoring its evolutionary and functional specialization within the kinome of vertebrates (milano2015tnni3kincardiovascular pages 2-3).

2. Reaction Catalyzed  
TNNI3K catalyzes a phosphorylation reaction using ATP as a phosphate donor, transferring a phosphate group to the hydroxyl group on serine and threonine residues of its target substrate proteins (ramzan2021anovelmissense pages 1-2). The enzymatic reaction can be summarized as follows: ATP + [protein]-(L-serine or L-threonine) → ADP + [protein]-(L-serine/threonine)-phosphate + H⁺, which is characteristic of serine/threonine-protein kinases (wang2013tnni3kisa pages 1-2). This phosphorylation event is central to the regulation of substrate activity, leading to subsequent alterations in protein conformation and function that are critical for cardiac muscle signaling (lal2014troponiniinteractingprotein pages 1-2).

3. Cofactor Requirements  
The catalytic activity of TNNI3K, like that of most protein kinases, is dependent on the presence of divalent metal ions, with magnesium (Mg²⁺) being the most common cofactor required to facilitate ATP binding and phosphate transfer during the catalytic process (wang2013tnni3kisa pages 1-2). Mg²⁺ serves to coordinate the phosphate groups of ATP within the active site, thereby promoting the formation of the enzyme-substrate complex necessary for efficient catalysis (ramzan2021anovelmissense pages 1-2).

4. Substrate Specificity  
The substrate specificity of TNNI3K is defined in part by its direct interaction with cardiac troponin I (cTnI), which is a major regulatory protein in the cardiac sarcomere (lal2014troponiniinteractingprotein pages 2-3). Experimental studies have demonstrated that TNNI3K phosphorylates cTnI primarily at specific serine and threonine residues, notably at Ser43 and Thr143, which are positions that overlap with known protein kinase C (PKC) target motifs (wang2013tnni3kisa pages 10-10, milano2015tnni3kincardiovascular pages 6-7). Although comprehensive consensus motifs for TNNI3K remain incompletely defined, its substrate recognition appears to be influenced by local sequence context that favors phosphorylation of serine/threonine residues in specific structural environments present in cTnI (wang2013tnni3kisa pages 8-10). This targeted phosphorylation suggests a role for TNNI3K in modulating cardiac contractility through fine-tuned control over myofilament function (milano2015tnni3kincardiovascular pages 2-3).

5. Structure  
TNNI3K is composed of a multi-domain structure that underpins both its catalytic function and regulatory potential; it comprises an N-terminal ankyrin repeat domain, a central catalytic kinase domain, and a C-terminal serine-rich domain (lal2014troponiniinteractingprotein pages 2-3, milano2015tnni3kincardiovascular pages 2-3). The ankyrin repeat domain is postulated to mediate protein-protein interactions that are critical for substrate binding and possibly for oligomerization or dimerization, thereby contributing to the spatial regulation of kinase activity (zhao2003cloningandcharacterization pages 2-3). The central kinase domain harbors the conserved catalytic motifs observed in serine/threonine kinases, including critical subdomains responsible for ATP binding, substrate recognition, and catalysis; within this domain, a conserved lysine residue (typically identified as K490 in mutagenesis studies) is essential for ATP coordination and overall kinase activity (zhao2003cloningandcharacterization pages 2-3, ramzan2021anovelmissense pages 1-2). The C-terminal serine-rich domain may serve as a regulatory module, potentially modulating kinase activity through intramolecular interactions or serving as a platform for post-translational modifications (milano2015tnni3kincardiovascular pages 2-3, pham2021thediverseroles pages 1-3). Although high-resolution crystal structures for TNNI3K have not been explicitly detailed in the provided literature, the domain organization is consistent with models generated through comparative analyses and predictive algorithms, which confirm that the kinase conforms to the typical three-dimensional fold associated with the eukaryotic protein kinase superfamily (zhao2003cloningandcharacterization pages 3-4).

6. Regulation  
Regulation of TNNI3K occurs at both the transcriptional and post-translational levels; its expression is highly cardiac-specific, driven by the action of the cardiac-enriched transcription factor MEF2C binding to promoter elements to ensure robust expression in cardiomyocytes (milano2015tnni3kincardiovascular pages 2-3). At the post-translational level, TNNI3K undergoes autophosphorylation, a modification critical for achieving full catalytic activity, and this autophosphorylation is dependent on the integrity of key catalytic residues within the kinase domain (zhao2003cloningandcharacterization pages 2-3, ramzan2021anovelmissense pages 1-2). In addition, interactions with specific inhibitory proteins such as peroxiredoxin 3 (PRDX3) may further modulate its kinase activity by binding to regions within the ankyrin repeat and kinase domains, thereby reducing its auto-phosphorylation and downstream signaling (lal2014troponiniinteractingprotein pages 2-3, milano2015tnni3kincardiovascular pages 2-3). Although phosphorylation sites beyond those involved in autophosphorylation have not been exhaustively mapped, the modular nature of TNNI3K suggests that its activity is finely tuned by both intramolecular regulatory motifs and extrinsic protein–protein interactions (milano2015tnni3kincardiovascular pages 7-7).

7. Function  
TNNI3K plays a central role in cardiac physiology, being expressed almost exclusively in cardiomyocytes where it contributes to the regulation of contractility and myocardial structure (milano2015tnni3kincardiovascular pages 1-2, lal2014troponiniinteractingprotein pages 2-3). One of its well-documented roles is the phosphorylation of cardiac troponin I (cTnI), which is a critical component of the sarcomeric complex that regulates muscle contraction in the heart; phosphorylation at residues such as Ser43 and Thr143 by TNNI3K modulates myofilament calcium sensitivity and contractile kinetics (wang2013tnni3kisa pages 10-10, milano2015tnni3kincardiovascular pages 6-7). In addition to its direct effects on contractile proteins, overexpression studies in murine models have linked elevated TNNI3K levels to adverse cardiac remodeling, cardiac hypertrophy, and altered conduction properties, including prolongation of the PR interval, which is indicative of impaired atrioventricular conduction (milano2015tnni3kincardiovascular pages 3-4, milano2015tnni3kincardiovascular pages 4-5). TNNI3K has further been implicated in the pathogenesis of ischemia/reperfusion injury; its kinase activity is associated with increased mitochondrial reactive oxygen species (ROS) production, contributing to oxidative stress and mitochondrial dysfunction in stressed cardiomyocytes, as evidenced by studies showing reduced injury upon inhibition of TNNI3K activity (vagnozzi2013inhibitionofthe pages 1-2, gu2023expressionlevelsof pages 11-13). Its precise role in cardiac signaling is underscored by the observation that TNNI3K not only phosphorylates cTnI but also likely participates in broader signaling networks that regulate cardiomyocyte survival, growth, and electrophysiological properties (pham2021thediverseroles pages 1-3, milano2015tnni3kincardiovascular pages 7-7).

8. Other Comments  
TNNI3K is of particular interest as a therapeutic target in cardiac diseases due to its cardiac-specific expression and its significant involvement in pathological conditions such as dilated cardiomyopathy, hypertrophic remodeling, and conduction system disorders (pham2023geneticburdenof pages 8-8, ramzan2021anovelmissense pages 1-2). Several small-molecule inhibitors have been developed to selectively target TNNI3K’s kinase activity, with compounds such as GSK854 and GSK329 demonstrating high potency and selectivity in preclinical models; these inhibitors have been shown to mitigate adverse remodeling and reduce infarct size in settings of ischemic injury (pham2021thediverseroles pages 8-9). Moreover, genetic studies have identified missense mutations within the kinase domain, such as the p.Ser511Pro variant, which affect ATP-binding and alter kinase conformation, thereby impairing TNNI3K’s catalytic function and contributing to familial cardiac conduction disease (ramzan2021anovelmissense pages 1-2, vagnozzi2013inhibitionofthe pages 2-3). Although the complete map of substrates for TNNI3K remains to be elucidated, its established interaction with cardiac troponin I positions it as a central mediator of sarcomeric function and cardiac contractility. Additionally, its regulation by both autophosphorylation and inhibitory interactions underscores the complexity of its role in modulating intracellular signaling. The identification of TNNI3K variants in patients with conduction abnormalities and cardiomyopathies further emphasizes its clinical relevance and fosters ongoing interest in fully characterizing its substrates, regulatory mechanisms, and structural features to better inform targeted therapeutic strategies (milano2015tnni3kincardiovascular pages 1-2, vagnozzi2013inhibitionofthe pages 1-2).

9. References  
1. Lal, H., Ahmad, F., Parikh, S., & Force, T. “Troponin I-interacting protein kinase: a novel cardiac-specific kinase, emerging as a molecular target for the treatment of cardiac disease.” Circulation Journal, vol. 78, no. 7, pp. 1514-1519, Jun 2014 (lal2014troponiniinteractingprotein pages 2-3).  
2. Milano, A., Lodder, E.M., & Bezzina, C.R. “Tnni3k in cardiovascular disease and prospects for therapy.” Journal of Molecular and Cellular Cardiology, vol. 82, pp. 167-173, May 2015 (milano2015tnni3kincardiovascular pages 1-2, milano2015tnni3kincardiovascular pages 2-3, milano2015tnni3kincardiovascular pages 3-4, milano2015tnni3kincardiovascular pages 4-5, milano2015tnni3kincardiovascular pages 6-7, milano2015tnni3kincardiovascular pages 7-7).  
3. Pham, C., Muñoz-Martín, N., & Lodder, E.M. “The diverse roles of tnni3k in cardiac disease and potential for treatment.” International Journal of Molecular Sciences, vol. 22, no. 6422, Jun 2021 (pham2021thediverseroles pages 1-3, pham2021thediverseroles pages 8-9, pham2021thediverseroles pages 11-12, pham2021thediverseroles pages 3-4).  
4. Zhao, Y., Meng, X.-M., Wei, Y.-J., Zhao, X.-W., Liu, D.-Q., Cao, H.-Q., Liew, C.-C., & Ding, J.-F. “Cloning and characterization of a novel cardiac-specific kinase that interacts specifically with cardiac troponin I.” Journal of Molecular Medicine, vol. 81, pp. 297-304, Apr 2003 (zhao2003cloningandcharacterization pages 1-2, zhao2003cloningandcharacterization pages 2-3, zhao2003cloningandcharacterization pages 3-4, zhao2003cloningandcharacterization pages 7-8).  
5. Ramzan, S., Tennstedt, S., Tariq, M., Khan, S., Noor Ul Ayan, H., Ali, A., Munz, M., Thiele, H., Korejo, A.A., Mughal, A.R., Jamal, S.Z., Nürnberg, P., Baig, S., Erdmann, J., & Ahmad, I. “A novel missense mutation in tnni3k causes recessively inherited cardiac conduction disease in a consanguineous pakistani family.” Genes, Aug 2021 (ramzan2021anovelmissense pages 1-2).  
6. Vagnozzi, R.J., Gatto, G.J., Kallander, L.S., Hoffman, N.E., Mallilankaraman, K., Ballard, V.L.T., Lawhorn, B.G., Stoy, P., Philp, J., Graves, A.P., Naito, Y., Lepore, J.J., Gao, E., Madesh, M., & Force, T. “Inhibition of the cardiomyocyte-specific kinase tnni3k limits oxidative stress, injury, and adverse remodeling in the ischemic heart.” Science Translational Medicine, vol. 5, 207ra141, Oct 2013 (vagnozzi2013inhibitionofthe pages 1-2, vagnozzi2013inhibitionofthe pages 2-3).  
7. Gu, Q., Orgil, B.-O., Bajpai, A.K., Chen, Y., Ashbrook, D.G., Starlard-Davenport, A., Towbin, J.A., Lebeche, D., Purevjav, E., Sheng, H., & Lu, L. “Expression levels of the tnni3k gene in the heart are highly associated with cardiac and glucose metabolism-related phenotypes and functional pathways.” International Journal of Molecular Sciences, vol. 24, no. 12759, Aug 2023 (gu2023expressionlevelsof pages 16-17, gu2023expressionlevelsof pages 7-8, gu2023expressionlevelsof pages 11-13).  
8. Pham, C., Andrzejczyk, K., Jurgens, S.J., Deprez, R.L., Palm, K.C.A., Vermeer, A.M.C., Nijman, J., Christiaans, I., Barge-Schaapveld, D.Q.C.M., van Dessel, P.F.H.M., Beekman, L., Choi, S.H., Lubitz, S.A., Skoric-Milosavljevic, D., van den Bersselaar, L., Jansen, P.R., Copier, J.S., Ellinor, P.T., Wilde, A.A.M., & Bezzina, C.R., Lodder, E.M. “Genetic burden of tnni3k in diagnostic testing of patients with dilated cardiomyopathy and supraventricular arrhythmias.” Circulation: Genomic and Precision Medicine, vol. 16, pp. 328-336, Aug 2023 (pham2023geneticburdenof pages 8-8).  
9. Yaron-Barir, T.M., Joughin, B.A., Huntsman, E.M., Kerelsky, A., Cizin, D.M., Cohen, B.M., et al. “The intrinsic substrate specificity of the human tyrosine kinome.” Nature, vol. 629, pp. 1174-1181, May 2024 (yaronbarir2024theintrinsicsubstrate pages 2-3).

References

1. (lal2014troponiniinteractingprotein pages 2-3): Hind Lal, F. Ahmad, S. Parikh, and T. Force. Troponin i-interacting protein kinase: a novel cardiac-specific kinase, emerging as a molecular target for the treatment of cardiac disease. Circulation journal : official journal of the Japanese Circulation Society, 78 7:1514-9, Jun 2014. URL: https://doi.org/10.1253/circj.cj-14-0543, doi:10.1253/circj.cj-14-0543. This article has 27 citations.

2. (milano2015tnni3kincardiovascular pages 1-2): Annalisa Milano, Elisabeth.M. Lodder, and Connie.R. Bezzina. Tnni3k in cardiovascular disease and prospects for therapy. Journal of Molecular and Cellular Cardiology, 82:167-173, May 2015. URL: https://doi.org/10.1016/j.yjmcc.2015.03.008, doi:10.1016/j.yjmcc.2015.03.008. This article has 20 citations and is from a domain leading peer-reviewed journal.

3. (milano2015tnni3kincardiovascular pages 2-3): Annalisa Milano, Elisabeth.M. Lodder, and Connie.R. Bezzina. Tnni3k in cardiovascular disease and prospects for therapy. Journal of Molecular and Cellular Cardiology, 82:167-173, May 2015. URL: https://doi.org/10.1016/j.yjmcc.2015.03.008, doi:10.1016/j.yjmcc.2015.03.008. This article has 20 citations and is from a domain leading peer-reviewed journal.

4. (milano2015tnni3kincardiovascular pages 3-4): Annalisa Milano, Elisabeth.M. Lodder, and Connie.R. Bezzina. Tnni3k in cardiovascular disease and prospects for therapy. Journal of Molecular and Cellular Cardiology, 82:167-173, May 2015. URL: https://doi.org/10.1016/j.yjmcc.2015.03.008, doi:10.1016/j.yjmcc.2015.03.008. This article has 20 citations and is from a domain leading peer-reviewed journal.

5. (milano2015tnni3kincardiovascular pages 4-5): Annalisa Milano, Elisabeth.M. Lodder, and Connie.R. Bezzina. Tnni3k in cardiovascular disease and prospects for therapy. Journal of Molecular and Cellular Cardiology, 82:167-173, May 2015. URL: https://doi.org/10.1016/j.yjmcc.2015.03.008, doi:10.1016/j.yjmcc.2015.03.008. This article has 20 citations and is from a domain leading peer-reviewed journal.

6. (milano2015tnni3kincardiovascular pages 6-7): Annalisa Milano, Elisabeth.M. Lodder, and Connie.R. Bezzina. Tnni3k in cardiovascular disease and prospects for therapy. Journal of Molecular and Cellular Cardiology, 82:167-173, May 2015. URL: https://doi.org/10.1016/j.yjmcc.2015.03.008, doi:10.1016/j.yjmcc.2015.03.008. This article has 20 citations and is from a domain leading peer-reviewed journal.

7. (milano2015tnni3kincardiovascular pages 7-7): Annalisa Milano, Elisabeth.M. Lodder, and Connie.R. Bezzina. Tnni3k in cardiovascular disease and prospects for therapy. Journal of Molecular and Cellular Cardiology, 82:167-173, May 2015. URL: https://doi.org/10.1016/j.yjmcc.2015.03.008, doi:10.1016/j.yjmcc.2015.03.008. This article has 20 citations and is from a domain leading peer-reviewed journal.

8. (pham2021thediverseroles pages 1-3): Caroline Pham, Noelia Muñoz-Martín, and Elisabeth M. Lodder. The diverse roles of tnni3k in cardiac disease and potential for treatment. International Journal of Molecular Sciences, 22:6422, Jun 2021. URL: https://doi.org/10.3390/ijms22126422, doi:10.3390/ijms22126422. This article has 19 citations and is from a peer-reviewed journal.

9. (wang2013tnni3kisa pages 1-2): Hui Wang, Lin Wang, Li Song, Yan-Wan Zhang, Jue Ye, Rui-Xia Xu, Na Shi, and Xian-Min Meng. Tnni3k is a novel mediator of myofilament function and phosphorylates cardiac troponin i. Brazilian Journal of Medical and Biological Research, pages 000-000, Feb 2013. URL: https://doi.org/10.1590/s0100-879x2013005002515, doi:10.1590/s0100-879x2013005002515. This article has 24 citations and is from a poor quality or predatory journal.

10. (wang2013tnni3kisa pages 10-10): Hui Wang, Lin Wang, Li Song, Yan-Wan Zhang, Jue Ye, Rui-Xia Xu, Na Shi, and Xian-Min Meng. Tnni3k is a novel mediator of myofilament function and phosphorylates cardiac troponin i. Brazilian Journal of Medical and Biological Research, pages 000-000, Feb 2013. URL: https://doi.org/10.1590/s0100-879x2013005002515, doi:10.1590/s0100-879x2013005002515. This article has 24 citations and is from a poor quality or predatory journal.

11. (wang2013tnni3kisa pages 8-10): Hui Wang, Lin Wang, Li Song, Yan-Wan Zhang, Jue Ye, Rui-Xia Xu, Na Shi, and Xian-Min Meng. Tnni3k is a novel mediator of myofilament function and phosphorylates cardiac troponin i. Brazilian Journal of Medical and Biological Research, pages 000-000, Feb 2013. URL: https://doi.org/10.1590/s0100-879x2013005002515, doi:10.1590/s0100-879x2013005002515. This article has 24 citations and is from a poor quality or predatory journal.

12. (zhao2003cloningandcharacterization pages 1-2): Yong Zhao, Xian-Min Meng, Ying-Jie Wei, Xiu-Wen Zhao, Dong-Qing Liu, Hui-Qing Cao, Choong-Chin Liew, and Jin-Feng Ding. Cloning and characterization of a novel cardiac-specific kinase that interacts specifically with cardiac troponin i. Journal of Molecular Medicine, 81:297-304, Apr 2003. URL: https://doi.org/10.1007/s00109-003-0427-x, doi:10.1007/s00109-003-0427-x. This article has 96 citations.

13. (zhao2003cloningandcharacterization pages 2-3): Yong Zhao, Xian-Min Meng, Ying-Jie Wei, Xiu-Wen Zhao, Dong-Qing Liu, Hui-Qing Cao, Choong-Chin Liew, and Jin-Feng Ding. Cloning and characterization of a novel cardiac-specific kinase that interacts specifically with cardiac troponin i. Journal of Molecular Medicine, 81:297-304, Apr 2003. URL: https://doi.org/10.1007/s00109-003-0427-x, doi:10.1007/s00109-003-0427-x. This article has 96 citations.

14. (zhao2003cloningandcharacterization pages 3-4): Yong Zhao, Xian-Min Meng, Ying-Jie Wei, Xiu-Wen Zhao, Dong-Qing Liu, Hui-Qing Cao, Choong-Chin Liew, and Jin-Feng Ding. Cloning and characterization of a novel cardiac-specific kinase that interacts specifically with cardiac troponin i. Journal of Molecular Medicine, 81:297-304, Apr 2003. URL: https://doi.org/10.1007/s00109-003-0427-x, doi:10.1007/s00109-003-0427-x. This article has 96 citations.

15. (zhao2003cloningandcharacterization pages 7-8): Yong Zhao, Xian-Min Meng, Ying-Jie Wei, Xiu-Wen Zhao, Dong-Qing Liu, Hui-Qing Cao, Choong-Chin Liew, and Jin-Feng Ding. Cloning and characterization of a novel cardiac-specific kinase that interacts specifically with cardiac troponin i. Journal of Molecular Medicine, 81:297-304, Apr 2003. URL: https://doi.org/10.1007/s00109-003-0427-x, doi:10.1007/s00109-003-0427-x. This article has 96 citations.

16. (gu2023expressionlevelsof pages 16-17): Qingqing Gu, Buyan-Ochir Orgil, Akhilesh Kumar Bajpai, Yufeng Chen, David G. Ashbrook, Athena Starlard-Davenport, Jeffrey A. Towbin, Djamel Lebeche, Enkhsaikhan Purevjav, Hongzhuan Sheng, and Lu Lu. Expression levels of the tnni3k gene in the heart are highly associated with cardiac and glucose metabolism-related phenotypes and functional pathways. International Journal of Molecular Sciences, 24:12759, Aug 2023. URL: https://doi.org/10.3390/ijms241612759, doi:10.3390/ijms241612759. This article has 3 citations and is from a peer-reviewed journal.

17. (lal2014troponiniinteractingprotein pages 1-2): Hind Lal, F. Ahmad, S. Parikh, and T. Force. Troponin i-interacting protein kinase: a novel cardiac-specific kinase, emerging as a molecular target for the treatment of cardiac disease. Circulation journal : official journal of the Japanese Circulation Society, 78 7:1514-9, Jun 2014. URL: https://doi.org/10.1253/circj.cj-14-0543, doi:10.1253/circj.cj-14-0543. This article has 27 citations.

18. (pham2021thediverseroles pages 8-9): Caroline Pham, Noelia Muñoz-Martín, and Elisabeth M. Lodder. The diverse roles of tnni3k in cardiac disease and potential for treatment. International Journal of Molecular Sciences, 22:6422, Jun 2021. URL: https://doi.org/10.3390/ijms22126422, doi:10.3390/ijms22126422. This article has 19 citations and is from a peer-reviewed journal.

19. (vagnozzi2013inhibitionofthe pages 1-2): Ronald J. Vagnozzi, Gregory J. Gatto, Lara S. Kallander, Nicholas E. Hoffman, Karthik Mallilankaraman, Victoria L. T. Ballard, Brian G. Lawhorn, Patrick Stoy, Joanne Philp, Alan P. Graves, Yoshiro Naito, John J. Lepore, Erhe Gao, Muniswamy Madesh, and Thomas Force. Inhibition of the cardiomyocyte-specific kinase tnni3k limits oxidative stress, injury, and adverse remodeling in the ischemic heart. Science Translational Medicine, 5:207ra141-207ra141, Oct 2013. URL: https://doi.org/10.1126/scitranslmed.3006479, doi:10.1126/scitranslmed.3006479. This article has 76 citations and is from a highest quality peer-reviewed journal.

20. (gu2023expressionlevelsof pages 7-8): Qingqing Gu, Buyan-Ochir Orgil, Akhilesh Kumar Bajpai, Yufeng Chen, David G. Ashbrook, Athena Starlard-Davenport, Jeffrey A. Towbin, Djamel Lebeche, Enkhsaikhan Purevjav, Hongzhuan Sheng, and Lu Lu. Expression levels of the tnni3k gene in the heart are highly associated with cardiac and glucose metabolism-related phenotypes and functional pathways. International Journal of Molecular Sciences, 24:12759, Aug 2023. URL: https://doi.org/10.3390/ijms241612759, doi:10.3390/ijms241612759. This article has 3 citations and is from a peer-reviewed journal.

21. (pham2021thediverseroles pages 11-12): Caroline Pham, Noelia Muñoz-Martín, and Elisabeth M. Lodder. The diverse roles of tnni3k in cardiac disease and potential for treatment. International Journal of Molecular Sciences, 22:6422, Jun 2021. URL: https://doi.org/10.3390/ijms22126422, doi:10.3390/ijms22126422. This article has 19 citations and is from a peer-reviewed journal.

22. (pham2023geneticburdenof pages 8-8): Caroline Pham, Karolina Andrzejczyk, Sean J. Jurgens, Ronald Lekanne Deprez, Kaylin C.A. Palm, Alexa M.C. Vermeer, Janneke Nijman, Imke Christiaans, Daniela Q.C.M. Barge-Schaapveld, Pascal F.H.M. van Dessel, Leander Beekman, Seung Hoan Choi, Steven A. Lubitz, Doris Skoric-Milosavljevic, Lisa van den Bersselaar, Philip R. Jansen, Jaël S. Copier, Patrick T. Ellinor, Arthur A.M. Wilde, Connie R. Bezzina, and Elisabeth M. Lodder. Genetic burden of <i>tnni3k</i> in diagnostic testing of patients with dilated cardiomyopathy and supraventricular arrhythmias. Circulation: Genomic and Precision Medicine, 16:328-336, Aug 2023. URL: https://doi.org/10.1161/circgen.122.003975, doi:10.1161/circgen.122.003975. This article has 6 citations.

23. (ramzan2021anovelmissense pages 1-2): Shafaq Ramzan, Stephanie Tennstedt, M. Tariq, Sheraz Khan, Hafiza Noor Ul Ayan, Aamir Ali, M. Munz, H. Thiele, Asad Aslam Korejo, Abdul Razzaq Mughal, S. Z. Jamal, P. Nürnberg, S. Baig, J. Erdmann, and Ilyas Ahmad. A novel missense mutation in tnni3k causes recessively inherited cardiac conduction disease in a consanguineous pakistani family. Genes, Aug 2021. URL: https://doi.org/10.3390/genes12081282, doi:10.3390/genes12081282. This article has 11 citations and is from a peer-reviewed journal.

24. (vagnozzi2013inhibitionofthe pages 2-3): Ronald J. Vagnozzi, Gregory J. Gatto, Lara S. Kallander, Nicholas E. Hoffman, Karthik Mallilankaraman, Victoria L. T. Ballard, Brian G. Lawhorn, Patrick Stoy, Joanne Philp, Alan P. Graves, Yoshiro Naito, John J. Lepore, Erhe Gao, Muniswamy Madesh, and Thomas Force. Inhibition of the cardiomyocyte-specific kinase tnni3k limits oxidative stress, injury, and adverse remodeling in the ischemic heart. Science Translational Medicine, 5:207ra141-207ra141, Oct 2013. URL: https://doi.org/10.1126/scitranslmed.3006479, doi:10.1126/scitranslmed.3006479. This article has 76 citations and is from a highest quality peer-reviewed journal.

25. (gu2023expressionlevelsof pages 11-13): Qingqing Gu, Buyan-Ochir Orgil, Akhilesh Kumar Bajpai, Yufeng Chen, David G. Ashbrook, Athena Starlard-Davenport, Jeffrey A. Towbin, Djamel Lebeche, Enkhsaikhan Purevjav, Hongzhuan Sheng, and Lu Lu. Expression levels of the tnni3k gene in the heart are highly associated with cardiac and glucose metabolism-related phenotypes and functional pathways. International Journal of Molecular Sciences, 24:12759, Aug 2023. URL: https://doi.org/10.3390/ijms241612759, doi:10.3390/ijms241612759. This article has 3 citations and is from a peer-reviewed journal.

26. (pham2021thediverseroles pages 3-4): Caroline Pham, Noelia Muñoz-Martín, and Elisabeth M. Lodder. The diverse roles of tnni3k in cardiac disease and potential for treatment. International Journal of Molecular Sciences, 22:6422, Jun 2021. URL: https://doi.org/10.3390/ijms22126422, doi:10.3390/ijms22126422. This article has 19 citations and is from a peer-reviewed journal.

27. (yaronbarir2024theintrinsicsubstrate pages 2-3): Tomer M. Yaron-Barir, Brian A. Joughin, Emily M. Huntsman, Alexander Kerelsky, Daniel M. Cizin, Benjamin M. Cohen, Amit Regev, Junho Song, Neil Vasan, Ting-Yu Lin, Jose M. Orozco, Christina Schoenherr, Cari Sagum, Mark T. Bedford, R. Max Wynn, Shih-Chia Tso, David T. Chuang, Lei Li, Shawn S.-C. Li, Pau Creixell, Konstantin Krismer, Mina Takegami, Harin Lee, Bin Zhang, Jingyi Lu, Ian Cossentino, Sean D. Landry, Mohamed Uduman, John Blenis, Olivier Elemento, Margaret C. Frame, Peter V. Hornbeck, Lewis C. Cantley, Benjamin E. Turk, Michael B. Yaffe, and Jared L. Johnson. The intrinsic substrate specificity of the human tyrosine kinome. Nature, 629:1174-1181, May 2024. URL: https://doi.org/10.1038/s41586-024-07407-y, doi:10.1038/s41586-024-07407-y. This article has 56 citations and is from a highest quality peer-reviewed journal.